Some interesting studies are being presented at 2010’s ASCO, in Chicago about the effectiveness of everolimus in HER-2 positive breast cancer (a mutation that affects about 25% of all breast cancers patients).
The point is about one single issue: everolimus and sirolimus are virtually the same drug, major difference is about blood clearance and half life.
Why not test sirolimus in breast cancer? It is cheaper (longer half life, less drug needed, older drug, large experience, use learning curve completed), it is safe … but surely not interesting for business …
See at:
Sirolimus vs everolimus: http://ht.ly/1Uths
One ASCO paper regarding everolimus: http://ht.ly/1UtjP
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment